| ￥3500 | |
| Z04723-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 90% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its ability to cleave a fluorogenic peptidesubstrate McaPLAQAVDpaRSSSRNH. Test result meets the standard. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 74.90 kDa | ||||
| Apparent Molecular Weight | Due to furin cleavage site, the mature form migrates to 65-115 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22μm filtered solution in 50mM Tris, 500mM NaCL, 0.005% Brij-35, 20% Glycerol (pH 8.5). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | A disintegrin and metalloproteinase 9 (ADAM9) is a member of the transmembrane ADAM family. It is expressed in different types of solid cancer and promotes tumor invasiveness. ADAM9 may be a prognostic marker for vestibular schwannomas (VS), and ADAM9 inhibition might have the potential as a systemic approach for the treatment of VS. |
| Synonyms | ADAM 9; Meltrin-gamma; Mdc9; Mltng; Adam9; Kiaa0021; AU020942; MDC9; mKIAA0021; CORD9; MCMP; MLTNG |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
